Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition
Lin Xia, Zaozao Zheng, Junyi Liu, et al.
Cancer Immunology Research (2021) Vol. 9, Iss. 6, pp. 707-722
Open Access | Times Cited: 50

Showing 1-25 of 50 citing articles:

Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer
Chenyi Luo, Peipei Wang, Siqi He, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 103
Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor (CAR) for tumor immunotherapy; recent progress
Hendrik Setia Budi, Firdaus Nuri Ahmad, Harun Achmad, et al.
Stem Cell Research & Therapy (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 47
Tumor buster - where will the CAR-T cell therapy ‘missile’ go?
Chunrun Qu, Hao Zhang, Hui Cao, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 47
Can EGFR be a therapeutic target in breast cancer?
Xi‐Yin Li, Lina Zhao, Ceshi Chen, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2022) Vol. 1877, Iss. 5, pp. 188789-188789
Closed Access | Times Cited: 45
Modulating tumor physical microenvironment for fueling CAR-T cell therapy
Zhong Luo, Xuemei Yao, Menghuan Li, et al.
Advanced Drug Delivery Reviews (2022) Vol. 185, pp. 114301-114301
Closed Access | Times Cited: 39
Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer
Xingyu Chen, Lixiang Feng, Yujing Huang, et al.
Cancers (2022) Vol. 15, Iss. 1, pp. 104-104
Open Access | Times Cited: 39
Role of Gut Microbiota in Breast Cancer and Drug Resistance
V Sathiyapriya, Sheetal Parida, Bhuvana Teja Lingipilli, et al.
Pathogens (2023) Vol. 12, Iss. 3, pp. 468-468
Open Access | Times Cited: 35
PILRα on tumor cells interacts with the T cell surface protein CD99 to suppress antitumor immunity
Xia Lin, Junyi Liu, Yu Chao, et al.
Nature Cancer (2025)
Closed Access | Times Cited: 1
Hurdles to breakthrough in CAR T cell therapy of solid tumors
Faroogh Marofi, Harun Achmad, Dmitry Olegovich Bokov, et al.
Stem Cell Research & Therapy (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 36
Exploring the Synergistic Effect of Tegafur-Syringic Acid Adduct Against Breast Cancer through DFT Computation, Spectroscopy, Pharmacokinetics and Molecular Docking Simulation
Azar Zochedh, Kaliraj Chandran, S. Athimoolam, et al.
Polycyclic aromatic compounds (2023), pp. 1-35
Closed Access | Times Cited: 20
CDK7 in breast cancer: mechanisms of action and therapeutic potential
Ying Gong, Huiping Li
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 8
The Immune Landscape of Breast Cancer: Strategies for Overcoming Immunotherapy Resistance
Kuba Retecki, Milena Seweryn, Agnieszka Graczyk‐Jarzynka, et al.
Cancers (2021) Vol. 13, Iss. 23, pp. 6012-6012
Open Access | Times Cited: 39
c-Met specific CAR-T cells as a targeted therapy for non-small cell lung cancer cell A549
Jingting Min, Chirong Long, Lu Zhang, et al.
Bioengineered (2022) Vol. 13, Iss. 4, pp. 9232-9248
Open Access | Times Cited: 23
Recent advancement in breast cancer treatment using CAR T cell therapy:- A review
Anuvab Dey, Subhrojyoti Ghosh, Shreya Jha, et al.
Advances in Cancer Biology - Metastasis (2023) Vol. 7, pp. 100090-100090
Open Access | Times Cited: 14
Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer
Yu Cao, Sergey Efetov, Mingze He, et al.
Archivum Immunologiae et Therapiae Experimentalis (2023) Vol. 71, Iss. 1
Closed Access | Times Cited: 14
Targeting CDK7 in oncology: The avenue forward
Zhimei Li, Guan Liu, Ya Gao, et al.
Pharmacology & Therapeutics (2022) Vol. 240, pp. 108229-108229
Closed Access | Times Cited: 20
NT5DC2 knockdown suppresses progression, glycolysis, and neuropathic pain in triple‐negative breast cancer by blocking the EGFR pathway
Rui Sang, Xiaoping Yu, Xia Han, et al.
Molecular Carcinogenesis (2024) Vol. 63, Iss. 4, pp. 785-796
Closed Access | Times Cited: 4
NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful Development
Ali Bashiri Dezfouli, Mina Yazdi, A. Graham Pockley, et al.
Cells (2021) Vol. 10, Iss. 12, pp. 3390-3390
Open Access | Times Cited: 26
Enhanced Chimeric Antigen Receptor T Cell Therapy through Co-Application of Synergistic Combination Partners
Sophia Stock, Anna-Kristina Kluever, Stefan Endres, et al.
Biomedicines (2022) Vol. 10, Iss. 2, pp. 307-307
Open Access | Times Cited: 19
Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer
Jong‐Ho Cha, Li-Chuan Chan, Ying‐Nai Wang, et al.
Journal of Biological Chemistry (2022) Vol. 298, Iss. 4, pp. 101817-101817
Open Access | Times Cited: 18
Epidermal growth factor potentiates EGFR(Y992/1173)-mediated therapeutic response of triple negative breast cancer cells to cold atmospheric plasma-activated medium
Peiyu Wang, Renwu Zhou, Rusen Zhou, et al.
Redox Biology (2023) Vol. 69, pp. 102976-102976
Open Access | Times Cited: 11
Gene Editing in ErbB/HER Family-Mediated Cancer Immunology
Ling Yin
IntechOpen eBooks (2025)
Closed Access
Establishment and Its Utility of a Patient-Derived Cell Xenografts (PDCX) Model with Cryopreserved Cancer Cells from Human Tumor
Ki Yeon Kim, Ji Min Lee, Eun Ji Lee, et al.
Cells (2025) Vol. 14, Iss. 5, pp. 325-325
Open Access
Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy
Saber Imani, Reyhaneh Farghadani, Ghazaal Roozitalab, et al.
Journal of Experimental & Clinical Cancer Research (2025) Vol. 44, Iss. 1
Open Access
CAR T Cell Strategies for Metastatic Breast Cancer
Payal D. Shah
Cancer immunotherapy (2025)
Closed Access
Page 1 - Next Page

Scroll to top